Current Report Filing (8-k)
November 18 2020 - 7:53AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM 8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): November 18, 2020 (November 18, 2020)
PLURISTEM
THERAPEUTICS INC.
(Exact
Name of Registrant as Specified in Its Charter)
Nevada
|
|
001-31392
|
|
98-0351734
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
MATAM
Advanced Technology Park
|
|
|
Building
No. 5
|
|
|
Haifa,
Israel
|
|
3508409
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
011
972 74 710 7171
(Registrant’s
telephone number, including area code)
Not
applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Stock, par
value $0.00001 per share
|
|
PSTI
|
|
The Nasdaq Capital
Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. Other Events.
On
November 18, 2020, Pluristem Therapeutics Inc., or the registrant, announced initial interim results from its Phase I study evaluating
PLX-R18 as a treatment for incomplete hematopoietic recovery following hematopoietic cell transplantation. The initial interim
results reflected an overall improvement observed in most patients, with the high-dose cohort showing clinically meaningful improvements
in hemoglobin (Hb); absolute neutrophil count (ANC), a measure of white blood cells; and platelet count (PLT). In this cohort,
Hb levels increased from 9.29±0.5 to 13.19±1.2 (p=0.0019), ANC increased from 1.09±0.6 to 5.13±1.7
(p=0.018) and PLT increased from 45.7±10 to 175.9±28 (p=0.000012). Treatment with PLX-R18 was found to be safe and
well-tolerated. In addition, the registrant reported that topline results from the full clinical study (n=21) are expected during
the first quarter of calendar year 2021.
Warning
Concerning Forward Looking Statements
This
Current Report on Form 8-K contains forward-looking statements within the meaning of the “safe harbor” provisions
of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, forward-looking statements are
being used when the registrant discusses the expected reporting of topline results from the full clinical study during the first
quarter of calendar year 2021. These forward-looking statements and their implications are based on the current expectations of
the management of the registrant only, and are subject to a number of factors and uncertainties that could cause actual results
to differ materially from those described in the forward-looking statements. The following factors, among others, could cause
actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements;
the registrant may encounter delays or obstacles in launching and/or successfully completing its clinical trials; the registrant’s
products may not be approved by regulatory agencies, the registrant’s technology may not be validated as it progresses further
and its methods may not be accepted by the scientific community; the registrant may be unable to retain or attract key employees
whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process;
the registrant’s products may wind up being more expensive than the registrant anticipates; results in the laboratory may
not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results
of human clinical trials; the registrant’s patents may not be sufficient; the registrant’s products may harm recipients;
changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market
share and pressure on pricing resulting from competition, which could cause the actual results or performance of the registrant
to differ materially from those contemplated in such forward-looking statements. In addition, historic results of scientific research
do not guarantee that the conclusions of future research would not suggest different conclusions or that historic results would
not be interpreted differently in light of additional research or otherwise. Except as otherwise required by law, the registrant
undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties
affecting the registrant, reference is made to the registrant’s reports filed from time to time with the Securities and
Exchange Commission.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
PLURISTEM THERAPEUTICS INC.
|
|
|
|
|
By:
|
/s/
Chen Franco-Yehuda
|
|
Name:
|
Chen Franco-Yehuda
|
|
Title:
|
Chief Financial Officer
|
Date:
November 18, 2020
2
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Sep 2023 to Sep 2024